Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COPD-CARhE
2024-516172-15-00Phase 2Authorised
- Sponsor
- Centre Hospitalier Universitaire de Montpellier
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of azithromycin in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Centre Hospitalier Universitaire de Montpellier. Primary endpoint: Number of exacerbations over 12 months of follow-up. Planned start Aug 2024; status: authorised.
02
Drugs
azithromycin
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2024-516172-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516172-15-00.